Home | Contact us | Disclaimer
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. The Company's lead CNS drug candidate is ELND005 for the treatment of agitation/aggression associated with Alzheimer's disease and Down syndrome. Transition's lead metabolic drug candidate is TT401 for the treatment of type 2 diabetes and accompanying obesity.

The Strategy

• Develop drugs to clinical Proof-of-Concept (Phase IIa)
• Partner with the pharma leader in the field

Therapeutic Focus

• CNS (Central Nervous System) disorders
• Metabolic diseases

Target Product Profile

• Disease-modifying, slowing disease progression
• Large age-related disease indications with unmet medical needs

© 2013 Transition Therapeutics Inc.